First Department of Pathology, School of Medicine, The National and Kapodistrian University of Athens, Athens, Greece.
Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Histopathology. 2024 Aug;85(2):347-352. doi: 10.1111/his.15211. Epub 2024 May 15.
PKC-fused blue naevi are a recently described group of melanocytic tumours that have distinctive morphological features, including a pigmented epithelioid melanocytoma-like junctional component or a dermal biphasic architecture associating with naevocytoid nests surrounded by dendritic and spindled pigmented melanocytes (so-called 'combined common and blue naevus'). There have been reports of smooth muscle hyperplasia in a hamartoma-like pattern in cases of combined blue naevi without genetic exploration.
Herein, we describe 12 cases of protein kinase C (PKC)-fused blue tumours associated with a co-existing smooth muscle hyperplasia, identified from a total of 98 PKC-fused melanocytic tumours. Archived slides of PKC-fused blue naevi with haematoxylin, eosin and phloxin staining, immunohistochemistry and molecular confirmation of a PKC-fusion by fluorescence in-situ hybridisation (FISH) or RNAseq were re-evaluated for identification of notable smooth muscle hyperplasia. Fifty-one of these slides had already been studied in a previous publication from our group.
The hyperplasia ranged from hypertrophic arrector pili muscles to extensive horizontal bundles of disorganised fibres constantly associated and limited within a biphasic dermal melanocytic component. At least one arrector pili muscle was always visible within the tumour, with occasionally direct extension of the hyperplastic fibres from the main muscle body. These muscle fibres were devoid of a PKC-fusion signal by FISH. PKC molecules are involved in the regulation of smooth muscle function, offering an explanatory framework.
These data suggest incorporating smooth muscle hyperplasia as a diagnostic morphological feature of PKC-fused blue melanocytic tumours.
融合蛋白激酶 C(PKC)的蓝色痣是一组最近描述的黑素细胞肿瘤,具有独特的形态学特征,包括色素上皮样黑色素瘤样交界成分或与巢状痣细胞样细胞相关的真皮双相结构,周围有树枝状和梭形色素性黑色素细胞(所谓的“混合性普通痣和蓝色痣”)。在没有遗传探索的情况下,曾有报告称在合并性蓝色痣中存在平滑肌呈错构瘤样增生。
本文描述了 12 例与共存平滑肌增生相关的 PKC 融合蓝色肿瘤,这些肿瘤是从总共 98 例 PKC 融合黑素细胞肿瘤中发现的。对 PKC 融合蓝色痣的存档切片进行苏木精、伊红和派洛宁染色、免疫组织化学检查,并通过荧光原位杂交(FISH)或 RNAseq 对 PKC 融合进行分子确认,以重新评估是否存在显著的平滑肌增生。其中 51 个切片已经在我们小组之前的一篇论文中进行了研究。
增生范围从肥厚的立毛肌到广泛的无组织纤维水平束,始终与双相真皮黑素细胞成分相关并受限。肿瘤内始终可见至少一个立毛肌,偶尔可见增生纤维直接从主要肌体延伸。这些肌肉纤维通过 FISH 缺乏 PKC 融合信号。PKC 分子参与平滑肌功能的调节,提供了一个解释框架。
这些数据表明,将平滑肌增生纳入 PKC 融合蓝色黑素细胞肿瘤的诊断形态学特征中。